Tuesday 17 November 2026 Sign in / SubscribeFree daily emailMarket analysisEnterpriseVigiEye regulatory newsCompePharma CRM & HR →
The business of pharma
Earnings

Omeros Q3 sales of Yartemlea rise 26% as CHMP upholds negative opinion on narsoplimab

Omeros reported $35.9M in net revenue for its stem cell transplant TMA drug, while the EMA's CHMP kept its negative opinion on the EU application after re-examination.

16 Nov 2026 · Omeros Corp OMER · Company news

Omeros Corp reported third-quarter 2026 results on 16 November, citing net revenue of $35.9M for Yartemlea (narsoplimab-wuug), up 26%. The product is approved in the US for transplant-associated thrombotic microangiopathy (TMA) following stem cell transplantation.

Subscribe to keep reading

$4.99 / month

  • Every article, analysis and opinion piece on CompePharma and VigiEye
  • One subscription for both sites, cancel any time

Already a subscriber? Enter your email below: we'll send you a sign-in link. No password needed.

We'll email you a link to confirm your address, then take you to secure checkout (Stripe). Billed monthly until you cancel; access starts at once, so the 14-day withdrawal right ends when it does. Already a subscriber? Enter your email and the link will sign you in. See our terms and privacy policy.

Company's press release (SEC filing): Omeros Corp ↗

Written by CompePharma's editorial system from the company's filing; claims are the company's. AI-assisted; check the source before acting. Not investment advice.

More EarningsAll →